Background-Kallistatin, a serine proteinase inhibitor, has vasodilatory and anti-inflammatory properties and is increased in other inflammatory conditions. We measured kallistatin in HIV for the first time, examined its relationship with inflammation, and determined if statin therapy affected levels.
INTRODUCTION
Patients with HIV are at increased risk of cardiovascular disease (CVD) compared with the general population (Triant, Lee, Hadigan and Grinspoon, 2007, Obel, Thomsen, Kronborg, Larsen, Hildebrandt, Sorensen and Gerstoft, 2007) . The increased risk is due in part to the independent effects of HIV infection despite virologic suppression with antiretroviral therapy (ART) (Grunfeld, Delaney, Wanke, Currier, Scherzer, Biggs, Tien, Shlipak, Sidney, Polak, O'Leary, Bacchetti and Kronmal, 2009, Ross, Rizk, O'Riordan, Dogra, El-Bejjani, Interestingly, kallistatin's effect on the upregulation of endothelial nitric oxide synthase is one of the same sites of action as 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) (Laufs, La Fata, Plutzky and Liao, 1998 , Martinez-Gonzalez, Raposo, Rodriguez and Badimon, 2001 , Kureishi, Luo, Shiojima, Bialik, Fulton, Lefer, Sessa and Walsh, 2000 , which are well-known to attenuate CVD risk by both their lipid-lowering and anti-inflammatory properties and may have an increasingly important role in the HIV population (Erlandson, Jiang, Debanne and McComsey, 2015, Eckard, Jiang, Debanne, Funderburg and McComsey, 2014) . In fact, two recent randomized, controlled trials recently showed that statin therapy produced dramatic reductions in non-calcified plaque volume measured by coronary CT angiography, reductions in the number of plaques with "vulnerable" or high-risk features (Lo, Lu, Ihenachor, Wei, Looby, Fitch, Oh, Zimmerman, Hwang, Abbara, Plutzky, Robbins, Tawakol, Hoffmann and Grinspoon) and halted the progression of carotid intima-media thickness (IMT), a surrogate marker of subclinical atherosclerosis (Longenecker, Jiang, Debanne, Labbato, Kinley, Storer and McComsey, 2015) . If kallistatin levels can help delineate CVD risk in HIV and/or are affected by statins, changes in kallistatin levels may offer another way to monitor these patients and/or measure the effects of interventions like statin therapy.
Only one study to date has evaluated the effects of statin therapy on kallistatin levels in the general population (Campbell, Kladis, Zhang, Jenkins, Prior, Yii, Kenny, Black and Kelly, 2010) . The authors reported no association between statin use and kallistatin levels in patients with and without Type 2 diabetes. However, this study was not randomized, included a very small number of patients who were undergoing coronary artery bypass graft surgery and were on different doses of various statins.
Thus, the main objectives of this study were to, for the first time, (1) measure kallistatin levels in a group of HIV-infected patients on ART, (2) examine the relationship between kallistatin levels and markers of inflammation and CVD risk in this population, and (3) determine the effect of statin use on kallistatin levels in the context of a placebo-controlled, randomized trial.
METHODS
The Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN in HIV (SATURN-HIV) is an on-going randomized, double-blinded, placebo-controlled trial designed to measure the effect of rosuvastatin on the progression of subclinical CVD in subjects with heightened inflammation or T-cell activation but normal low-density lipoprotein (LDL) cholesterol. Here, we present a post hoc analysis that assessed plasma kallistatin levels in SATURN-HIV participants at baseline and after 24 weeks of statin therapy or placebo.
Complete details of the SATURN-HIV trial can be found elsewhere (Eckard, Jiang, Debanne, Funderburg and McComsey, 2014) . Briefly, enrollment occurred between March 2011-August 2012 and included HIV-infected adults ≥18 years old with fasting LDLcholesterol ≤130 mg/dL and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L or CD8+ T-cell expression of CD38 and human leukocyte antigen (HLA)-DR antigens ≥19% at screening which occurred ≤30 days prior to enrollment. Additional inclusion criteria included cumulative ART duration ≥6 months, stable ART regimen for ≥12 weeks prior to entry, no plans to change current ART, diet, or exercise regimen, HIV-1 RNA <1,000 copies/mL, fasting triglycerides ≤500 mg/dL, Kamofsky performance score ≥80, and 1 CVD risk factor (i.e. male sex, smoking, hypertension, family history). Main exclusion criteria included a clinically-important illness or laboratory abnormality within 14 days prior to study entry that might place the subject at risk by being exposed to statins or which might confound the interpretation of this investigation, pregnancy/lactation, known CVD, uncontrolled diabetes (hemoglobin A1C ≥8.5%), active or chronic uncontrolled inflammatory condition or opportunistic infection, known underlying myositis/muscle disease, change in lipid or cholesterol modification pharmacotherapy or statin use in the 6 months prior to entry. The study enrolled at the University Hospitals Case Medical Center, Cleveland, OH and was reviewed and approved by the local institutional review board. Written informed consent was provided by all participants. The study was registered on clinicaltrials.gov (NCT01218802).
The intervention consisted of rosuvastatin 10 mg daily or matching placebo. Randomization was done by an investigational pharmacist and stratified by protease inhibitor (PI) use at entry. Participants underwent extensive cardiovascular assessment at pre-determined time points to evaluate for evidence of subclinical vascular disease by measuring carotid IMT, coronary artery calcium (CAC) score and flow-mediated vasodilation (FMD) of the brachial artery (baseline values presented in this current analysis). Plasma levels of inflammation (hsCRP, interleukin-6 (IL-6), soluble tumor necrosis factor receptor-I (sTNFR-I), soluble tumor necrosis factor receptor-II (sTNFR-II)), endothelial adhesion molecules (soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intracellular adhesion molecule-1 (sICAM-1)), and coagulation markers (D-dimer, fibrinogen) that are associated with CVD in HIV and/or in the general population and elevated in HIV were also measured (baseline and 24-week time point values presented in this current analysis). At each time point, a number of clinical and metabolic variables were also obtained, including fasting lipids, glucose and insulin. Physical examination and weight and height measurements were obtained in all subjects from the same scale, and blood pressure was obtained with an automated, calibrated blood pressure machine. An extensive review of the medical records was conducted and subject-reported data were collected, including demographics, past and current medical diagnoses, concomitant medications, and detailed ART history. HIV-1 RNA level and CD4+ cell count were collected as part of routine clinical care. SATURN-HIV participants were eligible for this current study if they had completed 24 weeks of intervention at the time of the analysis and had available stored plasma from both baseline and 24 weeks. Plasma was isolated at the time of the initial blood collection (which occurred after a 12-hour fast) and frozen at −70°C without prior thawing. Laboratory personnel were blinded to clinical information. Paired kallistatin levels (from the baseline and 24-week time points) were measured together in duplicate with a specific enzyme-linked immunosorbent (ELISA) assay (R&D Systems, Inc., Minneapolis, MN) as per the manufacturer's product manual. The calculated means of the measurements were used in the analysis. Inter-and intra-coefficients of variance (CV) were 3.6% and <8.1%, respectively.
Kallistatin levels were first analyzed with all subjects combined at the baseline time point. Continuous measures are described by medians and interquartile ranges (IQR), and nominal variables are described with frequencies and percentages. Differences in baseline kallistatin levels were also determined between several relevant sub-groups (e.g. male vs. female sex) using appropriate two-sample tests.
Between-group and within-group changes in kallistatin levels over 24 weeks in the statin and placebo groups were then considered. Here, variables are described by study group. Nominal variables were compared using χ 2 analysis or Fisher's exact test. For between-group comparisons (baseline and changes from baseline to 24 weeks), kallistatin levels were compared using Wilcoxon rank sum test. For within-group changes from baseline to 24 weeks, kallistatin levels were compared with Wilcoxon signed rank test.
Correlations between kallistatin levels and variables of interest were assessed using Spearman correlation coefficients for continuous variables. Correlations were first performed for variables at baseline for the HIV-infected group combined. Next, correlations were performed between changes in kallistatin levels and changes in other variables over the 24-week time point for the HIV-infected group combined.
The evaluation of kallistatin levels in this study was considered exploratory; no power calculations were determined. All statistical tests were two-sided with a 0.05 nominal significance level. Analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Among the entire study population (N = 147), a total of 135 (92%) HIV-infected subjects were included in this current analysis. Twenty-four, 64, and 47 subjects qualified for the study with hsCRP ≥2 μg/mL, CD8+CD38+HLA-DR+ cells ≥19%, or both, respectively. Table 1 shows demographic and baseline subject characteristics. Overall, the median age was 47 years with 81% male and 67% African American. The median CD4+ cell count was 578 cells/μL with a CD4+ cell count nadir of 177 cells/μL. The median duration of HIV infection was 136 months, with 49% on a PI-containing regimen.
The baseline median (IQR) kallistatin level for all the HIV-infected subjects was 28.4 (19.2, 40.0) μg/mL (Table 1 ). There were no significant differences between kallistatin levels and those subjects with a CAC score of 0 vs. >0, or between those with a detectable vs. undetectable HIV-1 RNA level, male vs. female sex, black vs. non-black race, or current smokers vs. non-smokers (Table 2) .
Baseline kallistatin levels were negatively correlated with hsCRP (R = −0.29; P = 0.0005), IL-6 (R = −0.23; P = 0.007) and fibrinogen (R = −0.23; P = 0.007), and positively correlated with homeostasis model assessment of insulin resistance (HOMA-IR) (R = 0.20; P = 0.04) ( Table 2 and Figure 1 ). High-sensitivity C-reactive protein and IL-6 values had one and two extreme outliers, respectively. Thus, these correlations were reconsidered with the outliers removed to ensure that these values were not driving the correlations. When removed, the P values remained significant for both correlations (hsCRP: R = −0.28; P = 0.0009 and IL-6: R = −0.21; P = 0.01). The hsCRP outlier and the highest IL-6 outlier were from the same subject.
There were no significant correlations between kallistatin levels and the other inflammation markers (sTNFR-I, sTNFR-II), the endothelial adhesion molecules (sVCAM-1, sICAM-1), and the coagulation marker, D-dimer. There were also no significant correlations between kallistatin levels and carotid IMT or FMD, nor any significant correlations between kallistatin and age, body mass index, blood pressure, LDL cholesterol, high-density lipoprotein cholesterol, and triglycerides (Table 2) .
Sixty-seven and 68 subjects were randomized to rosuvastatin and placebo, respectively. The statin and placebo groups were well-matched at baseline (Table 1) . Median (IQR) kallistatin levels at baseline were 30.5 (18.4, 39.5) μg/mL in the rosuvastatin arm and 26.5 (20.0, 41.1) μg/mL in the placebo arm (P = 1.00). Two subjects changed ART regimens between baseline and 24 weeks: one was started on abacavir instead of didanosine, and one stopped lamivudine/zidovudine and started emtricitabine/tenofovir and maraviroc. One subject stopped ART and had an HIV-1 RNA level of >12,000 copies/mL at 24 weeks, but there was no statistically significant difference in the number of subjects with an undetectable HIV-1 RNA level at baseline vs. 24 weeks in either group.
There was no significant difference between groups in kallistatin changes over the 24-week study period (rosuvastatin group: −0.9 (−12.8, 16.4) μg/mL; placebo group: 1.4 (−9.9, 13.2) μg/mL; P = 0.56). Similarly, at the 24-week time point, kallistatin levels remained unchanged in both groups (rosuvastatin group: 28.6 (23.1, 38.5) μg/mL; placebo group: 28.6 (20.5, 40.9) μg/mL; P = 0.93). As previously reported, there were also no significant differences in changes in inflammation and coagulation markers between subjects on rosuvastatin therapy vs. placebo (Eckard, Jiang, Debanne, Funderburg and McComsey, 2014) .
Correlations between changes in kallistatin levels and changes in variables of interest are presented in Table 2 . Changes in IL-6 and changes in kallistatin levels were significantly correlated for the HIV-infected group combined, and there was a trend towards significance between changes in hsCRP and changes in kallistatin (Figure 2 ). The same subject who was the outlier for baseline hsCRP was also the outlier for changes in hsCRP. When the analysis was re-considered this time without the outlier, the P value increased from 0.08 to 0.12 with little change in the correlation coefficient. The only other variable where changes were significantly correlated with changes in kallistatin was triglycerides.
DISCUSSION
In this study, and for the first time in HIV, we measured the level of the anti-inflammatory marker, kallistatin, in an HIV-infected population on ART with evidence of heightened inflammation and/or immune activation. The median plasma kallistatin level was 28.4 μg/mL for the HIV-infected group combined at baseline, which is comparable to the findings of a previous study in 318 healthy HIV-uninfected African American adolescents (Zhu, Chao, Kotak, Guo, Parikh, Bhagatwala, Dong, Patel, Houk, Chao and Dong, 2013) , which reported a mean (standard deviation (SD)) kallistatin level of 27.9 (11.2) μg/mL in males and 26.8 (11.0) μg/mL in females (P = 0.47). Chao, et al also reported a similar mean (SD) of 22.1 (3.5) μg/mL in 30 normal subjects (Chao, Schmaier, Chen, Yang and Chao, 1996) . Interestingly, Chao, et al also found significantly reduced mean kallistatin (SD) levels in subjects with liver disease (7.2 (2.5) μg/mL), sepsis (7.7 (3.5) μg/mL), in women taking oral contraceptives (19.8 (3.8) μg/mL), and during pregnancy (14.9 (3.3) μg/mL) (Chao, Schmaier, Chen, Yang and Chao, 1996) . Likewise, in a study of 54 patients with severe community-acquired pneumonia (CAP) who required intensive care unit (ICU) admission in a tertiary center in Taiwan, the median kallistatin level was 8.3 μg/mL on the day 1 of ICU admission and 11.0 μg/mL on the day 4 (Lin, Lu, Lin, Chen, Chao, Chao and Lin, 2013) . These studies suggest that acute illness and/or immune compromise may decrease kallistatin levels. One could argue that these subjects are more analogous to our current HIV-infected study group than healthy controls. However, this latter study was performed in a population that was much older (mean age of 77 years), in a setting of severe acute illness, and in a different ethnic group compared to our study population. The authors did include a control group that consisted of 17 healthy individuals who had a higher median (range) than the subjects admitted to the ICU with CAP (17.2 (5.3 -82.7) μg/mL), but they did not report any demographics or comparison to the study group. Likewise, our HIV-infected subjects were all on ART with well-controlled HIV, perhaps making them more like a healthy uninfected population. On the other hand, given the increased inflammation in this population (which would increase kallistatin levels) coupled with an immunocompromised state (which would decrease kallistatin levels), the sum effect may be "normal" kallistatin levels. Further studies are needed to investigate these potential situations by including additional groups, such as HIV-infected patients not on ART +/− low CD4 counts and patients with clinically-apparent co-morbidities, especially CVD, kidney disease, liver disease, and hypertension.
In this current study, we did demonstrate a significant negative correlation between kallistatin and the inflammatory cytokines, hsCRP and IL-6, which is consistent with findings in other studies (Zhu, Chao, Kotak, Guo, Parikh, Bhagatwala, Dong, Patel, Houk, Chao and Dong, 2013) , although data are conflicting (Jenkins, McBride, Januszewski, Karschimkus, Zhang, O'Neal, Nelson, Chung, Harper, Lyons and Ma, 2010) . While there was one hsCRP outlier and two IL-6 outliers at baseline, correlations did not change substantially when they were removed. There was also a significant correlation between changes in kallistatin levels and changes in IL-6 over 24 weeks (with no outliers present), indicating that this relationship is likely real. However, further studies should be conducted to verify this relationship as neither variable changed significantly over the 24-week time period.
It is unclear why there was not a significant relationship with either sTNFR-I or sTNFR-II, or if there is a clinical implication to the statistically significant relationship between kallistatin levels and either HOMA-IR or fibrinogen. These findings may suggest that the relationship between kallistatin and proinflammatory cytokines is more complex or altered in the setting of HIV. There was also no significant relationship between kallistatin and markers of subclinical vascular disease, and in particular, FMD, which is a measure of endothelial function. One previous study outside of HIV investigated kallistatin levels and carotid IMT in 60 children and adolescents with Type 1 diabetes (El-Asrar, Andrawes, Ismail and Salem, 2015) . Here, the authors showed a significant correlation between kallistatin levels and carotid IMT (left and right IMT, R=0.776 and R=0.881, respectively; both P<0.001). However, 30 of the diabetic subjects had evidence of microvascular complications, and these subjects had higher levels of kallistatin than those without microvascular complications. Thus, the lack of significant correlations between measures of endothelial dysfunction and subclinical atherosclerosis may be due to our chosen HIV population, none of whom had clinical evidence of vascular disease.
Interestingly, in the aforementioned study by El-Asrar, et al, the authors were able to differentiate patients with and without microvascular complications with a kallistatin cut-off value of 6.1 ng/mL with a sensitivity of 96.87% and a specificity of 93.75%. It is difficult to compare levels directly to our study, as the authors used a different method with a much different assay range than ours and other studies. However, this study suggests that kallistatin can be used as a biomarker for detection of microvascular complications in diabetic patients. Likewise, in Jenkins, et al (Jenkins, McBride, Januszewski, Karschimkus, Zhang, O'Neal, Nelson, Chung, Harper, Lyons and Ma, 2010) , the authors studied 116 Type 1 diabetic patients (50 with microvascular complications and 66 without microvascular complications) and 29 non-diabetic controls. The mean kallistatin level was 13.4 μg/mL in diabetics with complications, 12.1 μg/mL in diabetics with no complications, and 10.3 μg/mL in controls (ANOVA, P = 0.007). Thus, we believe these studies lend support to the idea of using kallistatin as a biomarker in the HIV-infected population to perhaps differentiate patients with and without micro-and macro-angiopathy. As discussed above, however, further studies are needed with various HIV sub-populations, including those with evidence of vascular disease.
In our current study, we also investigated whether statins affected kallistatin levels. Statins appear to be cardioprotective independent of their effects on LDL cholesterol. One of its non-lipid mechanisms is upregulating eNOS, thereby increasing endothelial nitric oxide levels (Laufs, La Fata, Plutzky and Liao, 1998, Martinez-Gonzalez, Raposo, Rodriguez and Badimon, 2001) . Given the overlap in the site of action between statins and kallistatin, it is reasonable to consider the effect of rosuvastatin on plasma kallistatin levels in the HIVinfected population. In our study, however, kallistatin levels were not affected by statin therapy, a finding that mirrors that of the only other available study in the general population (Campbell, Kladis, Zhang, Jenkins, Prior, Yii, Kenny, Black and Kelly, 2010) . Given the randomized, placebo-controlled design of this current study, our results provide greater evidence that statins given at normal therapeutic doses do not appear to directly affect plasma kallistatin levels. On the other hand, it is possible that we did not see a change in kallistatin levels because there were no significant changes in measured inflammatory markers in subjects on rosuvastatin therapy compared to those on placebo after 24 weeks. If the primary mechanism by which kallistatin levels change is by changes in inflammation, this could account, at least in part, for the lack of findings. However, statins have a number of pleotropic effects that that may have affected kallistatin levels, independent of changes in inflammatory cytokines.
There are limitations to this study. First, there was no healthy, HIV-negative control group to directly compare plasma kallistatin levels to that of the HIV-infected subjects. This study also investigated a specific HIV population: those on stable ART with low or undetectable HIV-1 RNA and normal LDL cholesterol. Thus, the generalizability to the HIV population as a whole should be determined in other studies. There are also statistical limitations to an exploratory post-hoc analysis, including potential sample size issues, which limits the overall interpretation of the data. This study investigated a number of associations between kallistatin and variables of interest, increasing the risk of Type I errors. Nevertheless, this study offers novel data, which can form the substrate for future research. Given its antiinflammatory properties, kallistatin should be further explored in the HIV population.
CONCLUSIONS
Kallistatin, a unique serine proteinase inhibitor, with vasodilatory and anti-inflammatory properties, was examined for the first time in HIV-infected patients. The median plasma level in HIV subjects who were virologically-suppressed on ART was comparable to studies in uninfected populations. Levels were negatively correlated with IL-6 and hsCRP, markers of systemic inflammation, but were not correlated with measures of subclinical CVD and were unaffected by 24 weeks of statin therapy. Given our findings with kallistatin and inflammatory cytokines and other studies showing kallistatin as a potential biomarker to detect microvascular complications in diabetics, kallistatin should be further explored in HIV-infected individuals. Studies particularly investigating patients with more comorbidities would be useful to evaluate kallistatin's utility as a biomarker in this unique population. Table 2 Relationships between Kallistatin Levels and Variables of Interest for All HIV-infected Subjects. 
A. Correlations between Kallistatin Levels and Variables of

